Educational intervention to help minorities make informed decisions about clinical trials
Official title: Prospective Cohort Study of a Patient Navigator PRE-ACT Educational Intervention to Promote Decision Making About Clinical Trials Among Racial and Ethnic Minorities
Run by Case Comprehensive Cancer Center · NCT05701085 · Data updated 2026-11-12
This study is testing a new way to help racial and ethnic minority patients feel more informed and confident about joining clinical trials.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 240 (estimated) |
| Sponsor | Case Comprehensive Cancer Center Academic / other |
| Locations | 1 site (Cleveland, Ohio) |
| Status | Recruiting |
| Started | April 24, 2023 |
| Main results expected | October 30, 2026 |
| Study ends | December 30, 2026 |
| Registry record updated | September 15, 2026 |
| Trial ID | NCT05701085 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are non-white or Hispanic patients aged 18 and older with a diagnosis of advanced or early-stage cancer.
✕Probably not a fit
Patients who are not racial or ethnic minorities or those who do not have a cancer diagnosis may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to address psychosocial barriers that prevent racial and ethnic minority patients from participating in clinical trials. By adapting the PRE-ACT model, the research will provide tailored information to improve knowledge and attitudes towards clinical trials among these underrepresented groups. The intervention will utilize a patient navigator model to enhance decision-making preparedness for clinical trial participation. The effectiveness of this approach is being evaluated in a population that was previously not well represented in similar studies.
Why it matters
Potential benefit: If successful, this intervention could empower minority patients to make informed decisions about participating in clinical trials, potentially improving their treatment options.
How similar studies have gone: While the PRE-ACT model has shown success in primarily white populations, its adaptation for diverse groups is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants must have a diagnosis of either advanced (metastatic) cancer or early stage disease for which they are undergoing oncological work-up, treatment or surveillance * Participants must be at least 18 years of age * Participants have a non-white race or Hispanic ethnicity recorded in their patient demographics in the electronic medical record * Participant must have a life expectancy greater than three months based on the primary oncology team's clinical assessment. * Participants must be able to read and verbally communicate in English. * Participants must provide written informed consent. Exclusion Criteria: \-
Where it's running
-
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States Recruiting
Study contacts
- Principal investigator: Lauren Chiec, MD — University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
- Study coordinator: Lauren Chiec, MD
- Email: lauren.chiec@uhhospitals.org
- Phone: 216-286-6741
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ARCS-based training to boost nursing students' communication, motivation, and confidence.
This study tries to see if an ARCS-based training program helps first-year nursing students improve their communication skills, learning motivation, and self-efficacy.
-
Robot-assisted bronchoscopy for peripheral lung lesions: comparing Monarch and ION platforms
Doctors are testing two FDA-cleared robotic bronchoscopy tools to see which more often successfully sample peripheral lung lesions during a bronchoscopy.
-
Safety and preliminary activity of BMS-986504 in unresectable MPNST
A new medicine called BMS-986504 is being tested to see if it is safe and may help people with unresectable malignant peripheral nerve sheath tumors, especially those whose tumors lack MTAP.
-
Wearable sensors and digital health in early cancer trials
This pilot study tests whether wearable activity tracking and electronic patient-reported outcomes can be feasibly used in early-phase cancer trials for adults.
-
HPV DNA-guided chemoradiation with Retifanlimab for locally advanced anal cancer
This study tests whether adjusting chemoradiation doses based on HPV ctDNA results and adding Retifanlimab after CRT can improve outcomes for adults with new, locally advanced anal cancer.
-
MiraBurst to help with changes in taste from cancer treatment
This study tests whether freeze-dried miracle fruit (MiraBurst) can improve taste changes in adults with solid tumors who are undergoing cancer treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.